

NUTRI NEWS



**Douglas
Laboratories®**
Raising the Standard for Nutrition and Wellness™

Recent health and nutrition information from Douglas Laboratories

March/April 2002

NUTRACEUTICAL APPROACHES TO CORONARY ARTERY DISEASE

Mitchell J. Ghen, D.O., Ph.D.

Outside of the medical/surgical model for heart disease, modern practitioners should consider complementary approaches to assist their patients. The stand-out difference between the two approaches is that the complementary strategy attempts to break the underlying pathology perpetuating the disease. The best example is arteriosclerotic cardiovascular disease, an epidemic malady of the industrialized nations. With so many products available today, it is best to approach the discussion by grouping nutraceuticals by their physiologic actions. Our nutritional knowledge base today helps us to recognize key areas of concern that must be addressed simulta-

neously. It is this concerted effort that should prove to have maximum impact on quality and quantity of life issues for the coronary artery disease patient. Therefore, we will consider the issues of *inflammation, infection, hormones, lipids, platelet aggregation, vasodilation, antioxidants, sympathetic tone, stress, insulin resistance and homocysteine*. You may note that several nutrients may be mentioned or noted twice due to their multiple types of action. It is best that you choose at least one from each of these categories, utilize the proper dose, evaluate the efficacy and then add or subtract substances depending on your patient's response. Though this article is

focusing on supplemental issues, there is a marked importance in appropriate dietary intervention as well.

Anticoagulants

One of the primary treatments applied for patients with coronary artery disease are anticoagulants. The aging process lends itself to increased coagulability. The obvious consequence of hypercoagulability is clot formation and subsequent artery occlusion. Increase in blood viscosity can create a hemodynamic state of ischemia, with its own set of circumstances. Ischemia is defined as low blood

continued on page 2

Table 1 – Anticoagulant Activity

Alpha-tocopherol	400-1600 I.U./day
Arginine	2000-6000 mg/day
Ascorbic acid	1000-4000 mg/day
Bromelain	500-3000 mg/day
<i>Curcuma longa</i>	200-1200 mg/day
E.D.T.A.-Oral or rectal suppository	Dose varies depending on renal fx
Essential Fatty Acids (EFAs)	5000-10,000 mg/day
Ginger (powdered)	1/2 to 1 tspn/3 times a day
<i>Ginkgo biloba</i>	40-120 mg/day
Inositol hexanicotinate	400-3000 mg/day
Magnesium	300-1600 mg/day
N-acetyl cysteine	500-3000 mg/day
Pancreatin	300 mg/day

INSIDE THIS ISSUE

- **Nutraceutical Approaches to Coronary Artery Disease**
 - Anticoagulantspage 1
 - Vasodilationpage 2
 - Lipid Modulationpage 2
 - Homocysteine Reductionpage 3
 - Antioxidants and Biological Enzymespage 5
 - Inflammation and Infectionpage 5
 - Sympathetic Tonepage 6
 - Inotropic and Chronotropic Augmentationpage 6
- **Gamma-Tocopherol**page 4
- **Coenzyme Q10: A Brief Description**page 7

flow, which may or may not have total obstruction associated with it. Ischemia can lead to apoptosis and inflammation. Evaluation of ischemic potential can be approached with a functional coagulation panel. This composite of tests includes the typical PT, PTT tests and also the more comprehensive combination of fibrinogen, prothrombin fragments one and two, thrombin-anti-thrombin complexes, soluble fibrin monomers and platelet CD62P (Selectin) receptors. A valuable test for evaluation of clotting is platelet aggregation testing. Platelet aggregation occurs with the presence of adenosine, epinephrine, collagen and thrombin. Most anti-platelet aggregation medications work only in the presence of adenosine (aspirin for example). This may explain why type A personalities using

Table 2 – Vasodilation

Arginine	3000-6000 mg/day
Garlic	400-600 mg/day
Hawthorne	160-250 mg of the flower (standardized)
Horse chestnut	600-700 mg (standardized to aecins)
Capsicum (cayenne)	40,000-100,000 heat units 1-6 capsules/day

aspirin still have clot formation. In contrast EDTA (ethylene diaminetetracetic acid), inhibits aggregation to all of the substances above with the exception of collagen. Acute phase reaction, particularly a high c-reactive protein, is related to vascular inflammation and or infection. Substances, such as coumadin affect prothrombin/thrombin activation. Natural products like vitamin E and magnesium have similar properties. Platelet hyperactivity is minimized by aspirin and similarly by other natural products like ginkgo and ginger. Fibrinogen/fibrin monomers can be addressed with enzymatic therapy like bromelain and pancreatin. Natural substances, that have similar reaction to heparin, are arginine, niacin, bromelain and papain. I have found clinically that increased fibrinogen levels of greater than 400 mg respond quickly and effectively to *Curcuma longa*.

Vasodilation

An important component to coronary artery disease treatment is vasodilation. The consequence of vasodilation is improved blood flow and subsequent increase in tissue oxygenation. The object of nitrates or nitrate therapy, a mainstay of both acute and chronic coronary arterial disease care is to increase blood flow to constricted blood vessels, whether this stricture is created by plaque

or by vasospasm. The natural substance, arginine, for example, is said to increase nitric oxide, a free radical (part of a group of compounds known as endothelial releasing factor, EDRF) that functions as a vasodilator. Nitric oxide has a secondary effect to potentially reduce the damage created by homocysteine. It has been hypothesized that EDTA's benefit can, to a large degree, be attributed to its release of nitric oxide. Of course, EDTA is an excellent anti-coagulant.

Also worthy of note, cayenne pepper has excellent effects on blood lipids, platelet activity, and vasodilatory action. As a wonderful first aid remedy, one teaspoon of cayenne in a glass of water can quickly relieve the discomfort of acute chest pain caused by angina.

Lipid Modulation

There are many products that effectively control dyslipidemia without the side effects often associated with conventional medical drugs. For elevated cholesterol, a combination of pantethine and inositol hexacotinate can demonstrate profound improvements in one month. For those patients with elevated triglyceride levels, L-Carnitine, as well as EFAs, can often solve the problem. I prefer the inositol hexanicotinate form of niacin due to its absence of the troublesome side

NUTRI NEWS


Publisher Peter W. Hefebe
Editor In Chief Andrew D. Halpner, Ph.D.
Assistant Editor Michael Traficante
Assistant Editor
& Research Natalie Shamitko
Technical Advisors/Contributors:
 Nita Bishop, Clinical Herbalist
 Martin P. Gallagher, M.S., D.C.
 Mitchell J. Ghen, D.O., Ph.D.
 Brad Lichtenstein, N.D.
 Derek DeSilva Jr., M.D.
 James Wilson, Ph.D.

Contact Us:
NutriNews
 600 Boyce Road
 Pittsburgh, PA 15205
 Phone: (412) 494-0122
 Fax: (412) 278-6804
 Internet: nutrinews@douglaslabs.com

Table 3 – Lipid Modulation

Pantethine	500-1,000 mg/day
Inositol hexanicotinate	3000 mg/day
Garlic	400-600 mg/day
L-Carnitine	1000-3000 mg/day
Essential Fatty Acids (EFAs)	5000-10,000 mg/day
MIC (methionine-inositol choline)	200-400 mg/day of each

Lpa (lipoprotein a) — decreasing agents

Inositol hexanicotinate	3000 mg/day
CoQ10	200-400 mg/day
Vitamin C	1000-2000 mg/day
L-Lysine	1000-2000 mg/day

effects of flush and liver irritation. Its mechanism of action is similar to all niacin compounds to reduce plasma triglycerides, VLDL, LDL synthesis and total cholesterol. Pantethine is the active hormone of pantethenic acid. It is considered to be one of the most important parts of coenzyme A (CoA) that transports fats to and from the cells. It has a potent effect on cholesterol as well as triglycerides. L-Carnitine is synthesized from lysine with the help of methionine. It improves triglyceride levels, total cholesterol and increases HDL. The n-3-polyunsaturated acids in large enough doses have been shown to be helpful in many studies. The DART study and most recently the GISSI study (published in The Lancet) are good examples. The role of omega-3 fatty acids are several, but recent studies report that their most profound effects may be on arrhythmogenesis as well as inflammation. The GISSI study reported a substantial decrease in cardiovascular events as a result of fish oil supplementation. I believe the study results, although impressive, would have been even more dramatic had the investi-

gation used omega-6 fatty acids as well. In refractory cases of elevated lipids, which have failed to respond to the above regimen, consider the combination of methionine, inositol and choline in doses of 200-400 mg of each taken 3 times daily. Lipoprotein a (Lpa) is an apolipoprotein, i.e. an LDL particle, to which an additional protein is attached. Because of Lpa's similarity with plasminogen, it interferes with fibrinolysis, and of course ultimately speeds up clot formation. Several substances as shown Table 3 can be helpful. Coenzyme Q10 for example, can inhibit the Lpa receptor expression.

Table 4 – Homocysteine Reduction

B6	10-50 mg/day
B12	1000-5000 mcg/day
Folate (folic acid)	800 mcg-5 mg/day
TMG (trimethylglycine)	250-1000 mg/day
Choline	200-1000 mg/day
Also helpful are: Serine, Glycine, and NAC (n-acetyl cysteine)	

Homocysteine Reduction

There are many published studies supporting homocysteine as a risk factor for vascular disease. Homocysteine has also been considered a good marker for

B6, B12 and folic acid deficiency. Even Raloxefen's benefit as seen in the Ruth Study "Raloxefen use for heart study" suggested this drug's action on coronary artery disease, may in part be due to its homocysteine-lowering qualities. Regular supplementation with the three B vitamins (B6, B12 and folate) will control a great majority of elevated homocysteine levels. A simple blood test confirming the patient's level of homocysteine should be performed with their annual routine exam. Although laboratories suggest that a level below 15 is normal, a level of less than 10 is ideal and less than 7 is considered optimal.

Insulin Resistance Reduction

Receptor sensitivity for insulin decreases and the body compensates by secreting increased amounts of insulin. This is known as 'insulin resistance'. Increased insulin levels promote lipogenesis, increased thrombosis from increase in plasminogen activator/inhibitor, and decreases through a hepatic mechanism, which will decrease HDL while increasing


triglyceride production. One of the most devastating effects is the glycosylation process, whereby circulating glucose attaches to proteins. Eventually this leads

continued on page 5

GAMMA-TOCOPHEROL: ITS IMPORTANCE AND UNIQUE PROPERTIES

When the term “vitamin E” is used, alpha-tocopherol is generally what comes to mind. However, vitamin E is actually a collective term that encompasses 3 other tocopherols (beta, gamma, and delta) in addition to alpha-tocopherol. These molecules are differentiated by the number and placement of methyl groups on their structure (see figure). Recent research has been revealing that gamma-tocopherol possesses some unique properties that allow it to function independently from as well as synergistically with alpha-tocopherol.

Alpha-tocopherol is the major form of vitamin E that can be found in blood as well as many tissues in humans. Due to its abundance in the body research has generally focused on alpha-tocopherol, with less emphasis on the other isomers. However, gamma-tocopherol is the major form of vitamin E consumed in the diet and is found in many plant seeds and the oils made from them. It has been estimated that gamma-tocopherol represents 70% of the vitamin E consumed in the typical US diet. Once in the body, the metabolism of alpha and gamma-tocopherol differs significantly. Alpha and gamma-tocopherol are absorbed similarly from the gastrointestinal tract and secreted into chylomicron particles without selective discrimination. However, when the chylomicron remnant particles are taken up by the liver, alpha-tocopherol is preferentially incorporated into very low-density lipoprotein (VLDL) cholesterol particles. This preferential placement of alpha compared with gamma-tocopherol into VLDL particles is a result of the presence of a protein in the liver called alpha-tocopherol transfer protein. This protein is able to recognize the stereochemistry of the various tocopherols and has the greatest affinity for the d-alpha form. Consequently, alpha-tocopherol becomes selectively located in VLDL particles, which after circulation and metabolism are transformed into low-density lipoprotein (LDL) particles. An interesting note is that supplementation with alpha-tocopherol in the absence of gamma-tocopherol leads to a reduction of both tissue and plasma levels of gamma-tocopherol. Nonetheless, given its presence in chylomicrons, and presence in other lipoprotein particles (albeit it at levels less than alpha-tocopherol) gamma-tocopherol does reach the circulation and plays an important role.



Alpha-tocopherol is generally thought of as the most powerful antioxidant of the various tocopherols, and due to its structure it can more readily donate electrons compared with gamma-tocopherol. Gamma-tocopherol, however, can better quench certain dangerous reactive nitrogen species such as peroxynitrate and nitrogen dioxide, both of which have been associated with a number of degenerative diseases. In fact, in relation to alpha-tocopherol it has been reported that gamma-tocopherol is superior in detoxifying nitrogen dioxide to less harmful compounds. In addition to its antioxidant properties, gamma-tocopherol has also been shown to possess anti-inflammatory properties and can inhibit the activity of cyclooxygenase-2 (COX-2) and production of prostaglandin E₂. Given the role that inflammation plays in the pathology of cardiovascular disease this finding is particularly important. Some researchers have also reported that gamma but not alpha-tocopherol levels are lower in those with cardiovascular disease compared with control subjects. Recent work has also brought to light a relationship between gamma-tocopherol

and prostate cancer. In a case-control study, the correlation between alpha-tocopherol, gamma-tocopherol, selenium intake and prostate cancer was examined. The researchers found a significant inverse correlation between the intake of gamma-tocopherol and the incidence of prostate cancer (i.e., the greater the intake of gamma-tocopherol, the lower the risk of disease). Most intriguing was that alpha-tocopherol and selenium intake was only protective when gamma-tocopherol intake was also high.

These interesting scientific findings, coupled with the fact that gamma-tocopherol, but not alpha-tocopherol levels have been shown to decline with age in humans give further credibility to the importance of supplementing with a well-rounded mixed tocopherol supplement that contains significant amounts of gamma-tocopherol.

Helzlsouer KJ., Huang HY., Alberg AJ., et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst* 2000;92:2018-2023.

Jiang Q., Christen S., Shigenaga MK., Ames BN. γ -Tocopherol, the major form of vitamin E in the US diet, deserves more attention. *Am J Clin Nutr* 2001;74:714-722.

Jiang Q., Elson-Schwab I., Courtemanche C., Ames BN. γ -Tocopherol and its major metabolite, in contrast to α -tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. *Proc Natl Acad Sci* 2000;97:11494-11499.

McLaughlin PJ., Weihrauch JL., Vitamin E content of foods. *J Am Diet Association* 1979;647-665.

Table 5 – Insulin Resistance Reduction

Soluble fibers	35-45 g/day
Chromium	200-1000 mcg day
Vanadium	1-2 mg/day
(higher doses often used for short periods of time)	
Cinnamon	1/2 tspn 3 times/day
C.L.A. (conjugated linoleic acid)	1-3 gm/day
EFA's	1-3 gm/day
Magnesium	800-2000 mg/day
Zinc	15-60 mg/day

to advanced glycosylation end products (AGE), which can be a precursor to microvascular disease. The abnormal glucose/insulin metabolism augments formation of free radicals. Of course, oxidative stress is often responsible for many of the factors contributing to coronary artery disease. Other than the substances noted in Table 5, caloric restriction is an excellent way to decrease free radical formation and improve insulin sensitivity. Equally as important is a regular exercise program given that insulin receptors are located within muscle tissue. In addition, repletion with antioxidants is also imperative (see Table 6).

Antioxidants and Biological Enzymes

There are many studies that support the importance of adequate antioxidant levels and the occurrence of coronary artery disease. In several instances, it has been postulated that antioxidant use is more important than the control of lipid levels. It is well known that cholesterol in itself is not problematic, but the exposure of cholesterol to the oxidation process certainly can generate plaque. Grapeseed extract, vitamin E and vitamin C are important components of antioxidant ther-

apy. Grapeseed extract alone has been shown to reduce plaque size. Since most diets have poor consumption of antioxidants and flavanoids, supplementation with larger doses than usual for coronary artery disease (C.A.D.) patients may be helpful.

Bromelain has been shown to have numerous therapeutic benefits, including effects on cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. Studies also give evidence that bromelain may inhibit platelet aggregation, an important car-

dioprotective property. Some have claimed that bromelain can not be effective orally, but this has since been refuted.

Researchers report that soluble fibers have a positive effect on hypertension as well as serum-fasting insulin. Patients should be regularly tested for glycosylated hemoglobin, fasting blood sugar and fasting insulin levels.

Inflammation and Infection

Presently, most recognize that there are several infectious agents that are associated with coronary vascular disease. Human herpes virus 6, nanobacteria, chlamydia and cytomegalo virus all have been implicated as part of the epigenesis of heart disease. Studies have even shown 89% of patients have chlamydia in their hearts at the time of bypass surgery. Most investigators agree that, although these infectious organisms may not be the primary cause of heart

Table 6 – Antioxidants & Biological Enzymes

<i>Antioxidants</i>	
Vitamin A	5000-10000 I.U./day
Vitamin C (buffered preferred)	1000-4000 mg/day
Vitamin E (unesterified, natural alpha-tocopherol with mixed tocopherols and tocotrienols)	800-1600 I.U./day
Selenium	200-1000 mcg/day
<i>Biological enzymes</i>	
SOD (superoxide dismutase)	2000-3000 MF/units
Catalase	2000-3000 MF/units

Table 7 – Inflammation and Infection

Bromelain (acid stable)	500-2000 mg/day
Papain	100-200 mg/day
Pancreatin	300 mg/day
Central fatty acids (EFAs)	5000-10000 mg/day
<i>Curcuma longa</i>	200-1200 mg/day
Vitamin C (buffered)	1000-4000 mg/day

disease, they significantly contribute to a hypercoagulable state. The use of low-dose broad-spectrum antibiotics such as tetracycline has been suggested along with aggressive enzyme usage. It seems that this combination affords the best result of reducing infection and inflammation. Several studies have shown the overall effectiveness of enzyme use is greater than the non-steroidal anti-inflammatories.

sequent increase in epinephrine/norepinephrine. Also, melatonin levels could possibly explain why the majority of heart attacks occur in the early morning hours. Melatonin has also been found to inhibit platelet aggregation. Saliva melatonin sampling can be obtained from several laboratories throughout the country.

Table 9 depicts several substances with either ionotropic (increase heart

seems to reduce the heart failure associated with low coenzyme Q10. Another study on the usefulness on coenzyme Q10 in clinical cardiology demonstrated large doses over time will reduce overall cardiac medication requirements significantly. (See insert on this page "Coenzyme Q10) Taurine, an amino acid has likewise been shown to have positive cardiac effects and diuretic properties. Hawthorne berry has been used for years by western herbologists as a good ionotropic natural agent.

Table 8 – Sympathetic Tone	
Melatonin0.5-10 mg/night

Sympathetic Tone

The sympathetic nervous system (flight or fight) plays an important role in C.A.D. Greater than usual sympathetic tone will increase heart rate and elevate blood pressure. Increased sympathetic activity has often been demonstrated in patients with C.A.D. Increased levels of adrenal medulla hormones, i.e., norepinephrine and epinephrine damage the arterial lining, increase platelet aggregation and increase oxidized cholesterol, all which lead to a faster generation of atherosclerosis. Remember, calcium stimulates sympathetic discharge, whereas, magnesium has antagonistic properties. Therefore, appropriate levels of magnesium and melatonin help to control an imbalanced sympathetic nervous system.

Researchers have demonstrated that patients with C.A.D. have nighttime melatonin levels that are 1/5 lower than healthy controls. Explanatory physiology is likely to be related to increased nighttime sympathetic discharge and the sub-

contractibility) or chronotropic (rhythm heart stabilizing) effects on the heart. Regular use of these substances can often augment typical conventional medications of similar nature, i.e., digitalis and antiarrhythmics. Several studies have shown magnesium to be an excellent preventative of dysrhythmias and can be especially useful in intravenous doses of 2-3 gm in the early stages of heart attack and for several days thereafter. Its use can prevent the serious rhythm disturbances that often accompany myocardial infarction. Long-term use is also suggested since most patients are magnesium deficient. Other studies have determined that the use of coenzyme Q10 in dosages of 300 mg/day one week prior to cardiac surgery improves three-fold the serum levels and tissue levels in the heart of this nutraceutical. This improvement

Summary

A multiangle assertive approach seems to be appropriate when treating the coronary artery disease patient. Hormonal issues should also be examined and a saliva profile may prove efficacious in determining DHEA, estrogen, progesterone, and testosterone levels. Recently, much has been written about hormones and their inverse relationship with coronary artery disease. By routinely screening with these saliva and blood tests, you will be able to note lipid levels, coagulability, glucose/insulin levels, melatonin level, hormone levels, inflammatory status, and homocysteine levels. A practitioner could then choose, from the tables provided, those nutritional supplements that would address areas of concern revealed by the test results.

Table 9 – Ionotropic and Chronotropic Augmentation	
Magnesium1600-3000 mg/day
Taurine2000-4000 mg/day
Hawthorne Berry250-500 mg/day
Coenzyme Q10200-400 mg/day

Abnormal tests would be noted and repeated after an appropriate length of treatment and adjustment of the treatment plan, by either increasing doses of already-prescribed nutraceuticals, with or without the addition of new agents. Further adjustment in the program would be necessary when the patient is taking concurrent medicine(s). Drugs that have similar properties to those nutraceuticals, that your patient is already taking, would require appropriate adjustment. For example, patients taking anti-coagulants would require lower doses of those supplements mentioned in Table 1. However, other patients, taking lipid-lowering drugs, may require increased doses of CoQ10. Remember, many coronary-related medications cause other nutritional deficiencies and I suggest that you refer to a text describing drug-herbal and drug-nutrient interactions.

Final thoughts:

The use of EDTA, although it is considered by the conventional medical community as controversial, has revealed in many studies to have a significant place in the treatment of coronary artery disease along side the nutraceuticals presented in this paper. Heavy metals do play a role in arterogenesis and should be studied further. Don't forget, in the midst of this complex array of nutraceuticals, water itself may improve the outcomes of coronary events. Simply drinking 4 or more glasses of pure water each day, can decrease myocardial infarction by more than 50%.

COENZYME Q10: A BRIEF DESCRIPTION

Coenzyme Q10, (CoQ10) also known as ubiquinone has been receiving an increasing amount of attention over the past 5 years for its cardioprotective abilities. CoQ10 is a fat-soluble molecule synthesized from cholesterol and located predominantly in mitochondria (the cell's powerhouse) where it plays a vital role in energy production. Specifically CoQ10 is crucial for the proper transfer of electrons through the mitochondrial respiratory chain. Given that heart muscle requires a tremendous amount of energy to function properly, it is not unusual that significant levels of CoQ10 can be found in heart muscle. Since CoQ10 levels have been found to be lower under certain circumstances, researchers have been investigating the effect that supplemental CoQ10 can have on heart function. Not surprisingly, numerous clinical studies have demonstrated improvements in functional parameters of the heart in patients with congestive heart failure after supplementation with CoQ10. CoQ10 treatment prior to bypass procedures has also yielded more positive outcomes when compared with patients who did not receive supplementation. CoQ10 levels have also been shown to be reduced in patients taking statin drugs, as cholesterol is required for the synthesis of CoQ10 in the body. CoQ10 has been shown to be an effective antioxidant, protecting against lipid peroxidation, DNA and protein oxidation and is also capable of functioning synergistically to help regenerate other antioxidants. The research community continues to find strong data indicating the benefits from supplementation with CoQ10, especially in the area of cardiovascular health as it relates to congestive heart failure.

References

- Arsenio, L., et al. Effectiveness of Long-Term Treatment with Pantethine in Patients with Dyslipidemias. *Clin Ther*, 1986; 8: 537-545.
- Baggio, E., et al. Italian Multicenter Study on the Safety and Efficacy of Coenzyme-Q-10 as Adjunctive Therapy in Heart Failure. Co-Q-10 Drug Surveillance Investigators. *Mol Aspects Med*, 1994; 15 Suppl: s287-294.
- Broughton, D.L., Taylor, R.L. Review: Deterioration of Glucose Tolerance with Age: The Role of Insulin Resistance: Age and Aging, 1991; 20: 221-225.
- Brugger, P., et al. Impaired Nocturnal Secretion of Melatonin in Coronary Artery Disease. *Lancet*, 1995; 345: 1408.
- Cantin, B., et al. Lipoprotein (a) An Independent Risk Factor for Ischemic Heart Disease in Men? The Quebec Cardiovascular Study. *J Am Cardiol*, 1998; 31:519-525.
- Cardinali, D.P., Del Zar, M.M., Vacas, M.I. The Effects of Melatonin in Human Platelets. *Acta Physiol Pharmacol Ther Latinoam*, 1993; 43: 1-13.
- Chappell, L.T., Stahl, J.P. The Correlation Between EDTA Chelation Therapy and Improvement in Cardiovascular Function: A Meta-Analysis. *J Adv Med*, 1993; 6: 139-160.
- Dabbs, J.M. Savory Testosterone Measurements: Collecting, Storing and Mailing Saliva Samples. *Physiology and Behavior*, 1991; 49: 815-817.
- El-Enein Ama, et al. The Role of Nicotinic Acid and Inositol Hexanicotinate as Anti-Cholesterolemic and Anti-lipemic Agents. *Nutr Rep Intl*, 1983; 28: 899-911.
- Folsom, A. Homocysteine: Not a Risk Factor. *Circulation* 98, 1998; 196-199, 204-210.
- Fox, M. More Evidence that Infections Cause Heart Disease. *Science News*, Sept 18, 2000.
- Fukagawa, N.K., Anderson, J.W., et al. High-Carbohydrate, High Fiber Diets Increase Peripheral Insulin Sensitivity in Healthy Young and Old Adults. *Am J Clin Nutr*, 1990; 52: 524-528.
- Ghen, M.J., et al. *The Advanced Guide to Longevity Medicine*. 2001, Landrum, South Carolina, pp. 193-201, 239-246.
- Graham, I.M., et al. Plasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project. *JAMA*, 1997; 277; 1775-1781.
- Hancke, C., Flytlie, K. Benefits of EDTA Chelation Therapy in Arteriosclerosis: A Retrospective Study of 47- Patients. *Journal of Advancement in Medicine*, 1993; 6(3); 161-172.
- Langsjoen, H., et al. Usefulness of Coenzyme-Q-10 in Clinical Cardiology: A Long Term Study. *Mol Aspects Med*, 1994; 15 Suppl: s165-175.
- Lipson, S.F., Ellison, P.T. Development of Protocols for the Application of Salivary Steroid Analysis to Field Conditions. *American Journal of Human Biology*, 1989; 1:249-255.
- Lukaczer, Dan. Nutritional Support for Insulin Resistance. *Applied Nutritional Science Reports*, July 2001; pp. 1-6.
- Maurer HR. Bromelain: biochemistry, pharmacology and medical use. *Cell Mol Life Sci* 2001;58:1234-45.
- Merghiolli, Robert, et al. Dietary Supplementation with N-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-PREVENZIONE Trial. *The Lancet*, Volume 234, Aug 7, 1999; pp 447-495.
- Mori, T.A., et al. Interactions Between Dietary Fat, Fish, and Fish Oils and their Effects on Platelet Function Men at Risk with Cardiovascular Disease. *Arterioscler Throm Vasc Biol*, 1997; 17:279-286.
- Phillips, R., Lemon, F., Kuzma, J. Coronary Heart Disease, Mortality Among Seventh Day Adventists with Differing Dietary Habits. *Am J Clin Nutr*, 1978 Oct 31;(10 Suppl): 5191-5198.
- Rosenfeldt, Franklin, et al. Experience with Coenzyme-Q-10 in Cardiac Surgery Patients. 2nd Conference of the International Co-Q-10 Association. Frankfurt, Germany, December 1-3, 2000.
- Watson, P.S., Scalia, G.M., et al. Lack of effect of Coenzyme-Q-10 on Left Ventricular Function in Patients with Congestive Heart Failure. *J Am Coll Cardiol*, 1999, May; 33(6):1549-1552.
- Weiss, Decker. Part One: Cardiovascular Disease Risk Factors and Fundamental Nutrition. *Applied Nutritional Science Reports*, Feb 2000, pp. 1-6.
- Welsh, A.L, Edele, M. Inositol Hexanicotinate for Improved Nicotinic Acid Therapy. *Int Record Med*, 1961; 174:9-15.
- Weiss, Decker. Part Two: Cardiovascular Disease Nutritional Management of Clinical Markers. *Applied Nutritional Science Reports*, Feb 2000, pp. 1-6.